The DEA has issued its Third Extension of COVID-19 Telemedicine Flexibilities, confirming that the current tele-prescription protocols for controlled substances will remain in place through December 31, 2025. Effective January 1, 2025, healthcare practitioners with a DEA registration in at least one state may continue to prescribe controlled medications via telemedicine without requiring an initial in-person evaluation.
This extension provides critical continuity for telemedicine providers, ensuring uninterrupted care for patients. However, significant amendments to these prescribing protocols are expected.
